FY2026 at a glance: NAV up 10% and portfolio momentum building
EPE Special Opportunities (ESO) has posted a solid year to 31 January 2026. Net Asset Value (NAV) per share rose 10% to 360 pence, helped by positive fair value movements across the portfolio. The share price barely moved – up 1% to 150 pence – which leaves a striking 58% discount to NAV.
Management leaned into balance sheet discipline: refinancing at Whittard returned cash to ESO, unsecured loan notes (ULN) were extended, and both ordinary and zero dividend preference (ZDP) shares were repurchased. Trading across core holdings improved, with Luceco ahead of expectations and consumer brands showing better momentum.
Key numbers investors should know
| NAV per share (31 Jan 2026) | 360 pence (+10% year-on-year) |
| Share price (31 Jan 2026) | 150 pence (+1% year-on-year) |
| Discount to NAV | 58% |
| Group profit for the year | £6.43 million (2025: £0.08 million) |
| Investments at fair value | £101.5 million |
| Liquidity | £14.1 million (includes cash in certain subsidiaries) |
| Ordinary share buybacks | 1.8 million shares at 147 pence average (6.2% of issued share capital retired) |
| ZDP shares in issue | 8.0 million, mature December 2026; carrying value £9.88 million |
| Unsecured loan notes | £4.0 million, 8.5% coupon, mature July 2026 |
| Portfolio leverage | 0.9x EBITDA (aggregate net third-party debt) |
| Unquoted portfolio valuation basis | 8.0x EV/EBITDA (mature assets) |
Quick jargon check: NAV is the per-share value of ESO’s assets minus liabilities. ZDP shares are preference shares that pay no dividends but redeem at a set amount on a future date. ULN are unsecured loan notes (company debt). EV/EBITDA is a common valuation multiple comparing enterprise value to earnings before interest, tax, depreciation and amortisation.
What powered the NAV gain: portfolio highlights
Luceco: ahead of expectations with cash generation
Luceco delivered revenue of £271 million (+12% year-on-year) and adjusted operating profit of £34 million, supported by strong EV charging demand and operational efficiencies. Adjusted free cash flow of £30 million reduced net leverage to 1.2x at year end. The company enters 2026 with positive momentum tied to energy transition markets.
Whittard: store growth, Asia build-out and a refinancing dividend to ESO
Whittard achieved its fifth straight year of sales growth and record EBITDA. Like-for-like sales in the UK retail estate rose 13% and new stores opened in key locations. The Asian strategy progressed with a third-party logistics hub in Hong Kong and more wholesale channels. Importantly for ESO’s liquidity, Whittard secured a £10.0 million term loan and a £2.0 million revolving credit facility in August 2025, using proceeds to repay ESO shareholder loans, which flowed back to the Company.
Rayware + LSA: building scale in homewares
Rayware improved sales momentum, notably in the US and online marketplaces. In July 2025 ESO acquired LSA International, investing up to £2.1 million in cash and issuing 298,013 ESO shares as part of the consideration. Integration into Rayware completed in February 2026 and is expected to deliver revenue and cost synergies that raise scale and profitability.
Pharmacy2U and Denzel’s: growth vectors at different stages
- Pharmacy2U: strong period with Services scaling rapidly (notably Online Doctor) and continued organic growth in eScript after integrating LloydsDirect.
- Denzel’s: strategy refocused on key retail accounts and marketplaces, with a COO appointed. ESO invested £0.4 million in March 2025 and is monitoring working capital to meet the plan.
Capital management: more liquidity, fewer shares
ESO ended the year with £14.1 million of liquidity and no third-party debt other than the ULN and ZDPs. Ordinary share buybacks totalled 1.8 million shares at 147 pence, and 1.5 million ZDP shares were repurchased, leaving 8.0 million in issue. The ULN maturity was extended to July 2026.
Why it matters: buybacks at a wide discount are accretive to NAV per share, and the Whittard refinancing returned £10.0 million to ESO, improving flexibility for portfolio support and selective new investments.
ULN and ZDP maturities: key dates in the diary
- ULN: £4.0 million due July 2026; interest expense for the year was £328,988.
- ZDPs: mature December 2026 with a final capital entitlement of 129.14 pence per share (not guaranteed; depends on asset coverage). Following buybacks, the gross redemption amount has been reduced to £10.4 million.
With low portfolio leverage (0.9x EBITDA) and £14.1 million liquidity, ESO has room to navigate these maturities, but they are still the main financing milestones to track.
Valuation gap: a 58% discount to NAV
The headline here is the discount: 150 pence share price vs 360 pence NAV per share. Management continues to address this through buybacks, portfolio development and aiming for greater diversification and scale. The unquoted portfolio is valued at 8.0x EV/EBITDA for mature assets, with a liquidity discount applied to public comparables. Sensitivities remain to broader equity markets and macro conditions, but the year’s £9.88 million net fair value uplift shows progress beneath the surface.
Risks to keep on the radar
- Macroeconomic and market risk: valuations remain exposed to equity market moves and interest rate conditions.
- Concentration: ESO deliberately runs a concentrated book; any single asset’s performance can swing NAV.
- Geopolitics: the RNS notes the late-February 2026 escalation in the Middle East, with potential knock-ons to markets, energy routes and sanctions risk.
- Debt maturities: ULN and ZDP redemptions in 2026 require continued prudent cash management.
Josh’s take: why this update matters
This is a cleaner, more confident set of numbers. A 10% NAV uplift, rising profitability (£6.43 million vs £0.08 million), better trading in key holdings, and a tidy capital structure all point in the right direction. The Whittard refinancing was smart – recycle capital back to ESO without forced asset sales. The Rayware/LSA combination could be a quiet compounding story if synergies drop through.
On the flip side, the market is unmoved for now, leaving a 58% discount. Part of that is the usual small-cap and private-markets scepticism. Part is the 2026 debt calendar (ULN, ZDP). Execution on disposals, refinancings or further cash returns could be the catalyst to narrow the gap. Until then, buybacks at 147 pence against a 360 pence NAV are doing some heavy lifting for per-share value.
What could move the shares next
- Formal progress on the ZDP and ULN refinancing/redemption plans.
- Realisation events or larger cash returns from portfolio companies.
- Further evidence of growth at Luceco, Pharmacy2U and Whittard translating into valuation uplifts.
- Additional buybacks if the discount persists and liquidity allows.
Bottom line
ESO has delivered NAV growth, tightened up its capital position and shown genuine portfolio momentum. The discount is wide, which cuts both ways: it signals caution, but also potential upside if 2026 brings clean execution on maturities and portfolio value creation. For patient investors who can live with a concentrated, private-markets strategy, this RNS reads positively.
